| Literature DB >> 28345784 |
Pichita Prasongvej1, Tongta Nanthakomon, Kankamol Jaisin, Athita Chanthasenanont, Supapen Lertvutivivat, Chamnan Tanprasertkul, Kornkarn Bhamarapravatana, Komsun Suwannarurk.
Abstract
Background : To determine a baseline quality of life (QoL) in cervical cancer survivors compared to that of healthy subjects in the tertiary Thammasat University Hospital, Thailand. Materials andEntities:
Keywords: Cervical cancer; quality of life; radical hysterectomy; concurrent chemoradiation
Year: 2017 PMID: 28345784 PMCID: PMC5454732 DOI: 10.22034/APJCP.2017.18.2.385
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Sociodemographic and Clinical Data in Women with no History of Malignant Neoplasm (Control) and Different Subgroups of Women Treated for Carcinoma of Cervix
| Control (n=95) | RH (n=37) | CRT (n=43) | RH+CRT (n=17) | p-value | |
|---|---|---|---|---|---|
| Current age[ | 45.6±9.8 | 50.9±8.2 | 54.5±11.1 | 57.9±9.8 | <0.001 |
| Underlying disease[ | 40(42.1) | 9(24.3) | 23(53.5) | 9(52.9) | 0.48 |
| Currently in a relationship[ | 86(90.5) | 30(81.1) | 19(44.2) | 10(58.8) | <0.001 |
| Children[ | 71(74.7) | 35(94.6) | 41(95.3) | 16(94.1) | 0.002 |
| Have occupation[ | 63(66.3) | 19(54.1) | 13(30.2) | 9(52.9) | 0.001 |
| Income < 10,000 baht[ | 25(26.3) | 22(59.5) | 35(81.4) | 12(70.6) | <0.001 |
| Education ≤ 2nd school[ | 36(37.9) | 31(83.8) | 39(90.7) | 15(88.2) | <0.001 |
| Family history of cancer[ | 25(26.3) | 8(21.6) | 10(23.3) | 3(17.6) | 0.853 |
, mean ± standard deviation (SD);
, n (%); RH, radical hysterectomy; CRT, concurrent chemoradiation;
, statistically significant differences.
Comparison of Oncologic Data between Subgroups of Women Treated for Carcinoma of Cervix
| RH(n=37) | CRT(n=43) | RH+CRT(n=17) | p-value | |
|---|---|---|---|---|
| Age (yr)[ | 46.2±9.7 | 50.4±10.8 | 53.0±9.8 | 0.053 |
| Stage (FIGO)[ | <0.001 | |||
| I | 37 (100) | 9 (20.9) | 10 (58.8) | |
| II | 0 | 20 (46.5) | 6 (35.3) | |
| III | 0 | 11(25.6) | 1 (5.9) | |
| IV | 0 | 3 (7.0) | 0 | |
| Time (yr)[ | 5.9±3.2 | 4.1±3.8 | 5.4±3.5 | 0.067 |
Age, age at time of treatment; FIGO, International Federation of Gynecology and Obstetrics; Time, time elapsed since treatment;
, mean ± standard deviation (SD);
, n (%); RH, radical hysterectomy; CRT, concurrent chemoradiation;
, statistically significant differences.
Quantitative Score (EORTC QLQ-C30) Compared Study to Control Groups
| Control[ | RH[ | CRT[ | RH+CRT[ | |
|---|---|---|---|---|
| Functional scales | ||||
| Physical function | 97.1±6.1 | -24.4 (-46.4,-2.5) | -34.5 (-53.6,-15.4) | -27.2 (-49.2,-5.4) |
| Role function | 92.8±18.7 | 3.6 (-3.4,10.6) | -8.7 (-15.3,-2.0) | -6.5 (-16.1,3.0) |
| Emotional function | 74.5±7.1 | 10.2 (0.6,19.8) | 1.8 (-13.5,17.1) | 3.8 (-9.8,17.3) |
| Cognitive function | 86.3±6.1 | 6.0 (-2.2,14.2) | 0.7 (-12.3,13.7) | 4.6 (-7.0,16.1) |
| Social function | 88.7±6.5 | 10.4 (1.7,19.2) | 3.2 (-10.8,17.1) | 3.7 (-8.7,16.1) |
| Global health/QoL | 55.2±6.8 | 22.2 (13.0,31.5) | 20.2 (5.4,34.9) | 22.0 (8.9,35.1) |
| Symptom scales | ||||
| Fatigue | 23.6±7.6 | -11.3 (-21.5,-1.0) | -0.3 (-16.6,16.0) | -6.7 (-21.2,7.8) |
| Nausea and Emesis | 9.1±4.8 | -5.6 (-12.1,0.8) | 1.2 (-9.1,11.5) | 0.3 (-8.9,9.4) |
| Pain | 17.1±7.2 | -2.3 (-12.1,7.5) | 16.6 (1.0,32.1) | 3.9 (-9.9,17.7) |
| Single item scales | ||||
| Dyspnea | 16.7±7.1 | -7.7 (-17.4,2.0) | -8.6 (-23.9,6.8) | -10.4 (-24.1,3.3) |
| Insomnia | 14.7±8.2 | -9.5 (-20.5,1.6) | -0.7 (-18.3,16.9) | -8.2 (-23.8,7.4) |
| Appetite loss | 5.9±6.9 | -12.6 (-21.9,-3.2) | -4.6 (-19.4,10.3) | -5.0 (-18.2,8.1) |
| Constipation | 9.7±8.7 | -4.1 (-15.9,7.6) | -5.1 (-23.9,13.6) | -6.1 (-22.7,10.6) |
| Diarrhea | 7.5±5.5 | -2.9 (-10.3,4.5) | 9.1 (-2.7,20.9) | 4.1 (-6.4,14.6) |
| Financial difficulties | 22.9±8.0 | -12.0 (-22.0,-1.3) | 3.4 (-13.7,20.5) | 2.5 (-12.7,17.7) |
, mean ± standard deviation (SD);
, mean difference from control group with CI (95% confidential interval); RH, radical hysterectomy; CRT, concurrent chemoradiation;
, statistically significant differences; QoL, quality of life.